Quintiles and London Genetics have entered a strategic alliance to offer pharmacogenetics solutions to the biopharmaceutical industry in an effort to advance personalized medicine. The two companies will collaborate to provide pharmacogenetic solutions, including novel biomarker and assay development services, aimed at helping clients access additional resources and speed the delivery of targeted treatments. Financial terms were not disclosed. “In the New Health, biopharmaceutical companies a...